Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | TACR2 | P21452 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851690 | 1.00 | PPARG (0.51) | PPARGPPARAMEN1GMNNEGFR | |
| SCHEMBL2852151 | 0.99 | PPARG (0.51) | PPARGPPARAMEN1GMNNEGFR | |
| SCHEMBL2852146 | 0.99 | PPARG (0.51) | PPARGPPARAMEN1GMNNEGFR | |
| SCHEMBL2853563 | 0.94 | PPARG (0.45) | PPARG | |
| SCHEMBL2854583 | 0.94 | PPARG (0.45) | PPARG | |
| SCHEMBL2854577 | 0.94 | PPARG (0.45) | PPARG | |
| SCHEMBL2853557 | 0.94 | PPARG (0.45) | PPARG | |
| SCHEMBL2851689 | 0.93 | PPARG (0.44) | PPARGPPARA | |
| SCHEMBL2851696 | 0.93 | PPARG (0.44) | PPARGPPARA | |
| SCHEMBL3439006 | 0.93 | PPARG (0.51) | PPARGPPARAMEN1GMNNEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575911-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-01-13 | — | — | EP | claimed |
| EP-1594884-B1 | ANTITUMORAL 18A-HOMOESTRA-1,3,5(10)-TRIEN-3-YL 2-SUBSTITUTED SULFAMATES | STERIX LTD (GB) | 2010-01-13 | — | — | EP | claimed |
| US-7452878-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-18 | — | — | US | claimed |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | US | claimed |
| US-7807669-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| EP-1575911-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-01-13 | — | — | EP | disclosed |
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-05 | — | — | US | disclosed |
| US-7452878-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-18 | — | — | US | disclosed |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062340-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE PPARY TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885MEN1 4700/4885 |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885MEN1 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.